Kinnate Biopharma Inc. (NASDAQ:KNTE) Receives Consensus Rating of “Hold” from Analysts

Kinnate Biopharma Inc. is a biotechnology company that specializes in developing and commercializing therapies for cancer and autoimmune diseases. The company's lead product candidate is KN-039, an antibody-drug conjugate (ADC) targeting CD33-expressing cells, which are involved in the development of acute myeloid leukemia (AML).

On August 18, 2021, Kinnate Biopharma announced that it had received a consensus rating of "Hold" from analysts covering the company. This means that the majority of analysts who cover the stock believe that the stock is not likely to outperform the market in the near term.

It's worth noting that this consensus rating is based on the opinions of individual analysts and may not necessarily reflect the views of all investors or stakeholders. Additionally, it's important to remember that past performance is not a guarantee of future results, and any investment decisions should be made carefully after considering all available information.